News stories about TearLab Corporation (NASDAQ:TEAR) (TSE:TLB) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TearLab Corporation earned a news impact score of 0.02 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 46.4444262842027 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

A number of analysts recently commented on the company. Zacks Investment Research upgraded TearLab Corporation from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a research report on Thursday, May 11th. HC Wainwright reiterated a “buy” rating and set a $4.00 price objective on shares of TearLab Corporation in a research report on Tuesday, May 16th. Finally, Rodman & Renshaw dropped their price objective on TearLab Corporation from $12.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, May 16th. Five equities research analysts have rated the stock with a buy rating, TearLab Corporation currently has an average rating of “Buy” and a consensus target price of $4.90.

TearLab Corporation (NASDAQ:TEAR) traded up 3.7954% during mid-day trading on Friday, reaching $1.3701. The company’s stock had a trading volume of 136,814 shares. The firm has a 50-day moving average of $1.96 and a 200 day moving average of $2.38. The firm’s market capitalization is $7.87 million. TearLab Corporation has a 1-year low of $1.20 and a 1-year high of $7.70.

TearLab Corporation (NASDAQ:TEAR) (TSE:TLB) last issued its earnings results on Monday, August 14th. The medical research company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.07. The firm had revenue of $7 million during the quarter, compared to analyst estimates of $6.86 million. During the same period in the previous year, the company earned ($0.08) earnings per share. The business’s revenue for the quarter was up 1.4% on a year-over-year basis. Equities analysts expect that TearLab Corporation will post ($2.76) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/09/08/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-tearlab-corporation-tear-share-price.html.

TearLab Corporation Company Profile

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.

Insider Buying and Selling by Quarter for TearLab Corporation (NASDAQ:TEAR)

Receive News & Stock Ratings for TearLab Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corporation and related stocks with our FREE daily email newsletter.